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Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: A link between a key
cell proliferative pathway and membrane synthesis
Abstract
Akt is a critical regulator of cell growth, proliferation, and survival that is activated by phosphatidylinositol
3-kinase (PI3K). We investigated the effect of PI3K inhibition on activation of sterol regulatory element
binding protein-2 (SREBP-2), a master regulator of cholesterol homeostasis. SREBP-2 processing
increased in response to various cholesterol depletion approaches (including statin treatment) and this
increase was blunted by treatment with a potent and specific inhibitor of PI3K, LY294002, or when a
plasmid encoding a dominant-negative form of Akt (DN-Akt) was expressed. LY294002 also suppressed
SREBP-2 processing induced by insulin-like growth factor-1. Furthermore, LY294002 treatment downregulated SREBP-2 or -1c gene targets and decreased cholesterol and fatty acid synthesis. Fluorescence
microscopy studies indicated that LY294002 disrupts transport of the SREBP escort protein, SCAP, from
the endoplasmic reticulum to the Golgi. This disruption was also shown by immunofluorescence staining
when DN-Akt was expressed. Taken together, our studies indicate that the PI3K/Akt pathway is involved in
SREBP-2 transport to the Golgi, contributing to the control of SREBP-2 activation. Our results provide a
crucial mechanistic link between the SREBP and PI3K/Akt pathways that may be reconciled teleologically
because synthesis of new membrane is an absolute requirement for cell growth and proliferation. © 2006
by The American Society for Cell Biology.
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Akt is a critical regulator of cell growth, proliferation, and survival that is activated by phosphatidylinositol 3-kinase
(PI3K). We investigated the effect of PI3K inhibition on activation of sterol regulatory element binding protein-2
(SREBP-2), a master regulator of cholesterol homeostasis. SREBP-2 processing increased in response to various cholesterol
depletion approaches (including statin treatment) and this increase was blunted by treatment with a potent and specific
inhibitor of PI3K, LY294002, or when a plasmid encoding a dominant-negative form of Akt (DN-Akt) was expressed.
LY294002 also suppressed SREBP-2 processing induced by insulin-like growth factor-1. Furthermore, LY294002 treatment
down-regulated SREBP-2 or -1c gene targets and decreased cholesterol and fatty acid synthesis. Fluorescence microscopy
studies indicated that LY294002 disrupts transport of the SREBP escort protein, SCAP, from the endoplasmic reticulum to
the Golgi. This disruption was also shown by immunofluorescence staining when DN-Akt was expressed. Taken together,
our studies indicate that the PI3K/Akt pathway is involved in SREBP-2 transport to the Golgi, contributing to the control
of SREBP-2 activation. Our results provide a crucial mechanistic link between the SREBP and PI3K/Akt pathways that
may be reconciled teleologically because synthesis of new membrane is an absolute requirement for cell growth and
proliferation.

INTRODUCTION
There is a growing body of work indicating a complex
interplay between growth regulatory signaling pathways
and lipid metabolism. Here we have used the 3-hydroxy-3methylglutaryl CoA (HMG-CoA) reductase inhibitors, referred to as statins, to study the link between the Akt cell
survival and proliferation pathway and the sterol-regulatory
element binding protein (SREBP) transcriptional pathway of
lipid homeostasis.
Statins are widely prescribed for the treatment of elevated
blood cholesterol levels in patients at risk of cardiovascular
disease. These agents exploit the cholesterol homeostatic
mechanism of the liver cell to which they are targeted by
reversibly inhibiting HMG-CoA reductase, the first ratelimiting enzyme in cholesterol biosynthesis. Deprived of
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newly synthesized cholesterol, the liver cell responds by
up-regulating low-density lipoprotein (LDL) receptor expression through activation of the SREBP pathway (Matsuda
et al., 2001). More LDL is subsequently cleared, resulting in
a reduction of circulating cholesterol levels.
SREBPs are master regulators of lipid homeostasis, inducing transcription of many genes involved in lipid biosynthesis (Goldstein et al., 2006). Genes involved in fatty acid
metabolism are preferentially regulated by SREBP-1c (e.g.,
fatty acid synthase [FAS]), whereas SREBP-2 principally regulates genes involved in cholesterol metabolism (e.g., HMGCoA reductase) and uptake (LDL-receptor; Horton et al., 2003).
SREBPs are produced as precursors embedded in the membrane of the endoplasmic reticulum (ER) bound to the cholesterol sensor, SREBP cleavage-activating protein (SCAP). When
cholesterol levels are sensed to be low, SCAP escorts SREBP via
COPII vesicles to the Golgi where it is processed by two proteases, designated Site-1 protease and Site-2 protease, to an
active transcription factor. When cholesterol levels are sensed
to be sufficient by SCAP, the SCAP/SREBP complex is held
back in the ER by a retention protein (Insig-1 or -2). Therefore,
exit of SCAP/SREBP from the ER is the critical point in
feedback regulation of cholesterol metabolism (Nohturfft
et al., 2000; Brown et al., 2002; Espenshade et al., 2002;
Yang et al., 2002). Statins activate SREBP (Yang et al., 1995;
Cheng et al., 1999), presumably by inhibiting cholesterol
synthesis and hence reducing the regulatory pool sensed
by SCAP.
There is a growing body of clinical and experimental evidence that statins exert additional benefits beyond cholesterol
reduction (Laufs and Liao, 2003). For example, statins increase
nitric oxide production by endothelial cells and promote angiogenesis through activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway (Shiojima and Walsh, 2002). Akt,
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also called protein kinase B, is a critical regulator of PI3Kmediated cell growth and survival (Shiojima and Walsh, 2002;
Song et al., 2005). Akt is recruited to the plasma membrane by
its pleckstrin homology domain, which is targeted to the lipid
products of PI3K. Activation of Akt then occurs through sequential phosphorylation of a threonine and serine residue.
LY294002 and wortmannin are two PI3K inhibitors that inhibit
Akt activation. These PI3K inhibitors also inhibit activation of
SREBP-1 in response to growth factors (VEGF, platelet-derived
growth factor [PDGF]) and insulin (Demoulin et al., 2004; Zhou
et al., 2004; Hegarty et al., 2005), suggesting a role for PI3K/Akt
in lipogenesis. Therefore, given that statins can activate both
SREBP and PI3K/Akt pathways, we hypothesized that the
activation of SREBP by statins may involve PI3K/Akt. We
report here that the PI3K/Akt pathway has a fundamental
effect on cholesterol homeostasis beyond statins, influencing
SREBP-2 processing through effects on the ER-to-Golgi transport of this transcription factor.
MATERIALS AND METHODS
Materials
All solvents were analytical reagent- or HPLC-grade from Crown Scientific
(Minto, NSW, Australia). Dulbecco’s modified eagle’s medium/Ham’s Nutrient Mixture F-12 (DMEM/F12) was obtained from JRH Biosciences (Lenexa,
KS). l-glutamine, newborn calf serum (NBS), fetal calf serum (FCS), and
penicillin-streptomycin were obtained from Invitrogen (Carlsbad, CA). Lipoprotein-deficient NBS was prepared as described (Goldstein et al., 1983).
Compactin (also called mevastatin), 2-hydroxypropyl- ␤ -cyclodextrin,
LY294002, methyl- ␤ -cyclodextrin, mevalonate, Dulbecco’s phosphatebuffered saline (PBS), protease inhibitors (or cocktail), phosphatase inhibitor
cocktail, Triton X-100, essentially fatty-acid free bovine serum albumin (BSA),
saponin, and brefeldin A were obtained from Sigma (St. Louis, MO). Insulinlike growth factor-1 (IGF-1) was purchased from Bio-Scientific (Gymea, NSW,
Australia). Cholesterol and 25-hydroxycholesterol (cholest-5-en-3␤, 25-diol;
25HC) were obtained from Steraloids (Newport, RI). Cholesterol complexed
to methyl-␤-cyclodextrin was prepared as described (Brown et al., 2002).
[1-14C]Acetic acid, sodium salt (56 mCi/mmol), and [1-14C]oleic acid (55
mCi/mmol) were obtained from GE Healthcare (Chalfont St Giles, United
Kingdom). Atorvastatin, fluvastatin, lovastatin, (p)itavastatin, pravastatin,
rosuvastatin, and simvastatin were obtained from Sequoia Research Products
(Oxford, United Kingdom). The squalene epoxidase inhibitor, GR144000X,
was kindly donated by Glaxo-Smith Kline (Middlesex, United Kingdom).
Rabbit polyclonal antibodies against phospho-Akt (Ser473) or total Akt were
obtained from Cell Signaling Technology (Beverly, MA). Anti-Myc IgG-9E10
mouse monoclonal antibody (mAb; epitope corresponding to amino acids
408-439 within the C-terminal domain of c-Myc of human origin) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Chinese hamster
ovary (CHO) cells and antibodies against SCAP and SREBP-2 were kind gifts
of Drs. Michael S. Brown and Joseph L. Goldstein (UT Southwestern, Dallas,
TX): IgG-R139, a rabbit polyclonal antibody against hamster SCAP (amino
acids 54-277 and 540-707; Sakai et al., 1997); IgG-7D4, a mouse mAb against
hamster SREBP-2 (amino acids 32-250; Yang et al., 1994). Mammalian expression plasmids, also generously provided by Drs. Brown and Goldstein, have
been previously described: pCMV-PLAP-BP2 (513-1141; Sakai et al., 1998),
pCMV-Insig-1-Myc (Yang et al., 2002), and pTK-SCAP (Nohturfft et al., 1998).
The plasmids for wild-type Akt (pCMV-WT-Akt-myc) and dominantnegative Akt (pCMV-DN-Akt-myc, T308A, S473A Akt) were kindly provided
by Dr. Stefanie Dimmeler (University of Frankfurt, Germany; Dimmeler et al.,
1999).

Cell Culture
CHO cells were grown as a monolayer in a humidified incubator at 37°C in a
5% CO2 atmosphere. The culture media were DMEM/F12 containing penicillin (100 U/ml), streptomycin (100 g/ml), and l-glutamine (2 mM), supplemented with various sera. The different media used were supplemented as
follows: medium A, 5% (vol/vol) NBS; medium B, 5% lipoprotein-deficient
NBS; medium C, 5% NBS plus 5 g/ml cholesterol, 1 mM sodium mevalonate, 20 M sodium oleate; medium D, 5% lipoprotein-deficient NBS plus 1
g/ml 25HC; and medium E, 0.1% (wt/vol) BSA. Statins, 25HC, LY294002
and other test agents were added in ethanol or dimethylsulfoxide (DMSO).
Within an experiment, the final concentrations of ethanol or DMSO were kept
constant between conditions and did not exceed 0.25% (vol/vol).

Generation of Stably Transfected 13A/PS Cell Line
On day 0, SRD-13A cells (Rawson et al., 1999), a SCAP-deficient cell line
derived from CHO-7 cells, were set up in a six-well plate at 2 ⫻ 105 cells per
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well in medium C. On day 1, the cells were cotransfected with pCMV-PLAPBP2 (0.5 g) and pTK-SCAP (0.5 g) using FuGENE 6 transfection reagent
(Roche Diagnostics, Basel, Switzerland). On day 2, the cells were switched to
medium B to select for cells expressing the SCAP-containing plasmid. Fresh
medium B was added every 2–3 d until colonies formed at ⬃15 d. Individual
colonies were cloned by limiting dilution and screened for expression of the
secreted form of PLAP (see below). The most robust colonies were further
tested for 16 h in medium B in the presence or absence of sterols (10 g/ml
cholesterol and 1 g/ml 25HC). A cell line, designated 13A/PS, that showed
clear and consistent sterol-regulation of PLAP secretion was maintained in
medium B and used as a tool to quantify SREBP-2 processing.

Analysis of SREBP-2 Processing by the Secreted Alkaline
Phosphatase Assay
On day 0, 13A/PS cells were set up in 12-well plates in medium B at 1 ⫻ 105
cells per well. On day 2, cells were rinsed with PBS, refed fresh medium B,
and incubated with various additions as described in the figure legends. After
incubation for 16 h, the media were collected for determination of secreted
PLAP (SEAP Gene Reporter Assay, Roche Diagnostics) and cells harvested for
cell protein determination (BCA kit; Pierce, Rockford, IL; Du et al., 2004). In
some experiments involving IGF-1 treatment, cells were cultured in medium
E for 24 h before incubation with various additions, as described in the figure
legends.

Analysis of SREBP-2 Processing by Western Blotting
SREBP-2 processing by Western blotting was analyzed as described (Adams
et al., 2004) with minor modifications. On day 0, 13A/PS cells (medium B, or
medium E for IGF-1 treatment experiments) or a cell line, SRD-1, overexpressing the truncated mature form of SREBP-2 (medium D; Metherall et al., 1989)
were set up at 1 ⫻ 106 cells per 100-mm dish or 6 ⫻ 105 cells per 60-mm dish.
On day 2, the cells were fed medium B or medium E (for IGF-1 treatment
experiments) and incubated with various additions for varying times as
described in the figure legends. After incubation, the cells were washed once
with cold PBS, resuspended in 500 l of buffer A (10 mM Tris-HCl, pH 7.6, 100
mM NaCl, 1% [wt/vol] SDS) containing 10 l of Protease Inhibitor Cocktail,
and then passed through a 22-gauge needle 15 times. The resultant cell lysates
were then shaken for 20 min at room temperature. The protein concentration
of each whole cell lysate was measured (BCA kit; Pierce, Rockford, IL) after
which an aliquot (50 g) was analyzed by SDS-polyacrylamide gel electrophoresis (PAGE; 7.5% wt/vol) and immunoblotting (see below).

Analysis of Akt Phosphorylation
On day 0, 13A/PS cells were set up in medium B at 1 ⫻ 106 cells per 100-mm
dish. On day 2, the cells were refed fresh medium B and incubated with
various additions for varying times as described in the figure legends. After
incubation, the cells were washed twice with cold PBS containing 0.01 volume
of Phosphatase Inhibitor Cocktail and then lysed in Phosphosafe Extraction
Buffer (Merck, Rahway, NJ; 100 l) containing Protease Inhibitor Cocktail (4 l),
Phosphatase Inhibitor Cocktail (2 l), and other protease inhibitors (25 g/ml
N-acetyl-leucinal-leucinal-norleucinal [ALLN], 1 g/ml pepstatin A, 2 g/ml
aprotinin, 10 g/ml leupeptin, 200 M phenylmethylsulfonyl fluoride). The
resultant cell lysates were passed through a 20-gauge needle 40 times. The
protein concentration of each whole cell lysate was measured (BCA kit; Pierce)
after which an aliquot (80 g) was analyzed by SDS-PAGE (10% wt/vol) and
immunoblotting (see below).

SCAP-Insig-1– binding Assay
Coimmunoprecipitaton of Insig-1 and SCAP was performed as described
(Feramisco et al., 2005) with the following modifications. On day 0, SRD-13A
cells were set up in medium C at 1 ⫻ 106 cells per 100-mm dish. On day 2, cells
were transfected with pTK-SCAP (4.5 g) and pCMV-Insig-1-Myc (0.9 g) in
medium A using FuGene 6 transfection reagent (Roche Diagnostics). The total
amount of DNA was adjusted to 6 g/dish with pcDNA3 and/or pTK3 mock
vectors. On day 3, the cells were washed once with PBS, switched to medium
B, and incubated with various additions as indicated. After incubation for
16 h, cells were rinsed twice with cold PBS and harvested for immunoprecipitation with monoclonal anti-Myc IgG-9E10 as described (Feramisco et al.,
2005). Immunoprecipitated pellets and supernatants were analyzed by SDS/
PAGE (10% wt/vol) and immunoblotting (see below).

Immunoblot Analysis
Samples were mixed with 0.25 volume of buffer B (250 mM Tris-HCl, pH 6.8,
10% [wt/vol] SDS, 25% (vol/vol) glycerol, 0.2% (wt/vol) bromphenol blue,
and 5% (vol/vol) ␤-mercaptoethanol), boiled for 5 min at 95°C, and then
subjected to 7.5% or 10% SDS-PAGE. After electrophoresis, the proteins were
transferred to Hybond-C nitrocellulose filters (GE Healthcare). Incubations
with primary antibodies were performed at 4°C using the following antibodies: 5 g/ml IgG-7D4 (SREBP-2); 5 g/ml IgG-R139 (SCAP); 0.4 g/ml
anti-Myc IgG-9E10 (Myc-Insig-1); 1:1000 dilution of polyclonal Phospho-Akt
(Ser473) antibody (P-Akt), and 1:1000 dilution of Akt antibody (total Akt).
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Akt, SREBP, and ER-to-Golgi Transport
Secondary antibodies were peroxidase-conjugated AffiniPure donkey antirabbit or donkey anti-mouse IgG (H⫹L; Jackson ImmunoResearch Laboratories, West Grove, PA) used at a 1:5000 dilution. The bound antibodies were
visualized by ECL Western blotting detection reagent (GE Healthcare). The
filters were exposed to Hyperfilm ECL (GE Healthcare) for periods of 2 s to
3 min. The relative intensities of bands were quantified using Sciencelab
ImageGauge 4.0 Software (Fujifilm, Tokyo, Japan).

RNA Isolation and Gene Expression Analysis by
Quantitative Reverse Transcriptase-PCR
On day 0, 13A/PS and CHO-7 cells were set up in six-well plates in medium
B at 2.5 ⫻ 105 cells per well. On day 2, the cells were rinsed with PBS, refed
fresh medium B, and incubated with various additions as described in the
figure legends. After incubation for 16 h, cells were harvested for total RNA
using Tri Reagent (Sigma) according to the manufacturer’s instructions. Total
RNA was quantified by spectrophotometry (Nanodrop ND-100 Spectrophotometer, Bio-Lab, St. Paul, MN). Reverse transcriptase-PCR was performed on
1 g of RNA according to the manufacturer’s protocol for the SuperScript III
First Strand cDNA Synthesis Kit (Invitrogen). Quantitative reverse transcriptase-PCR (QRT-PCR) was performed using iQSupermix (Bio-Rad, Richmond,
CA) on an ABI 7700 Sequence Detector and analyzed using ABI Prism
Sequence Detector Soft-ware v1.6.3 (PE Biosystems, Foster City, CA). Primer
pairs (Sigma) used for the amplification reaction of various genes from
cDNAs are tabulated in Supplementary Data. PCR products were verified by
sequencing. The change in gene expression levels was determined by normalizing mRNA levels of the gene of interest to the mRNA level of the
housekeeping gene, porphobilinogen deaminase (PBGD). Melting curve analysis was performed to confirm the production of a single product in each
reaction.

Cholesterol and Fatty Acid Synthesis Assay
On day 0, CHO-7 and 13A/PS cells were set up at a density of 4 ⫻ 105
cells/dish in 60-mm dishes in medium B. On day 2, cells were refed fresh
medium B and incubated with various additions plus 1 Ci/ml [1-14C]acetic
acid. After incubation for 16 h, cells were washed twice with buffer C (5 mM
Tris HCl, pH 7.5, 150 mM NaCl) containing 0.2% (wt/vol) BSA and twice in
buffer C alone. Cells were lysed with NaOH (0.1 M; 1 ml), and the lysates were
saponified with 1 ml of 75% (wt/vol) KOH, 2 ml of ethanol plus 1 l of
butylated-hydroxytoluene (20 mM), and 20 l of EDTA (20 mM) at 70°C for
1 h. After cooling, nonsaponifiable lipids were extracted into hexane (3 ⫻ 3
ml) and evaporated to dryness under a steam of nitrogen gas. For cholesterol
synthesis, lipid extracts were redissolved in hexane (100 l) and separated by
argentation TLC using 4% (wt/vol) silver-coated Silica Gel 60 F254 plates
(Merck, Whitehouse Station, NJ) and a mobile phase of heptane:ethyl acetate
(2:1, vol/vol), developed four times. This method separates cholesterol from
its major precursors including desmosterol. For fatty acid synthesis, fatty
acids were extracted into hexane (3 ⫻ 3 ml) from the same samples after
acidification with hydrochloric acid (10 M; 3 ml). Hexane extracts were
evaporated, redissolved in hexane (150 l) and separated by TLC using Silica
Gel 60 F254 plates with a mobile phase of heptane:diethyl ether:glacial acetic
acid (90:30:1, vol/vol/v). For visualization, TLC plates were exposed to
BAS-MS imaging plate (Fujifilm) for 24 or 72 h at room temperature and
scanned by FLA-5100 phosphoimager (Fujifilm).

Cholesterol Esterification Assay
On day 0, 13A/PS cells were set up at a density of 4 ⫻ 105 cells/dish in 60-mm
dishes in medium B. On day 2, cells were treated with varying agents in
medium B plus 1 Ci/ml [1-14C]oleic acid. After incubation for 16 h, lipids
were extracted from the cell lysate as described (Du et al., 2004). The extracts
were redissolved in hexane (60 l) and separated by TLC using Silica Gel 60
F254 plates with a mobile phase of heptane:diethyl ether:glacial acetic acid
(90:30:1, vol/vol/vol). For visualization, TLC plates were exposed to BAS-MS
imaging plate (Fujifilm) for 72 h at room temperature and scanned by FLA5100 phosphoimager (Fujifilm). The extent of cholesterol esterification was
quantified using Sciencelab ImageGauge 4.0 software (Fujifilm).

Fluorescence Microscopy
On day 0, CHO/pGFP-SCAP cells (Nohturfft et al., 2000), a cell line stably
expressing GFP-SCAP, were set up in six-well plates containing sterile 19 ⫻
19-mm glass coverslips at 2 ⫻ 105 cells per well in medium B. On day 1, cells
were washed with PBS, refed 2 ml of medium B, and incubated with various
additions for 4 h as indicated in the figure legends. In some experiments
involving IGF-1 treatment, cells were cultured in medium E for 24 h before
incubation with various additions. After incubation, cells were rinsed once
with PBS and fixed with 1 ml of 3% (vol/vol) formaldehyde/PBS for 10 min
at room temperature. Cells were then rinsed twice with PBS and mounted on
glass slides with mounting media containing anti-fading reagent (Biomeda,
Foster City, CA). Images were obtained using a Leica TCS SP laser scanning
spectral confocal microscope (Deerfield, IL). GFP was excited with the 488-nm
laser lines from an argon laser. Confocal image stacks were edited using Leica
Confocal Software, LCS Lite.
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Immunofluorescence Staining
On day 0, CHO/pGFP-SCAP cells were set up as above. On day 1, cells were
transfected with myc-tagged wild-type Akt (WT-Akt) or dominant-negative
Akt (DN-Akt) plasmids (1 g/well) by using FuGene 6 transfection reagent
according to the manufacturer’s instructions (Roche Diagnostics). On day 2,
cells were refed 2 ml of medium B per well and incubated with compactin (5
M) for 4 h. After incubation, the media were aspirated, and the cells were
fixed with 1 ml of 3% (vol/vol) formaldehyde for 10 min at room temperature.
Cells were rinsed with PBS (three times for 5 min) and then permeabilized
with 0.1% (vol/vol) Triton X-100 in PBS (1 ml, 2 min). After washing with PBS
(three times for 5 min), cells were incubated with 10% (vol/vol) FCS in PBS
for 30 min at room temperature. Cells on the coverslips were then incubated
with primary antibody against myc-tag (IgG 9E10, 1.8 g/ml in 10% FCS in
PBS plus 0.1% [wt/vol] of saponin) for 16 h at 4°C. After washing with PBS
(three times for 10 min), cells were incubated with 5 g/ml Alexa Fluro-568 –
conjugated secondary antibody (Molecular Probes, Eugene, OR) for 1 h at
room temperature. Cells were washed with PBS (three times for 10 min) and
then mounted on glass slides with mounting media containing anti-fading
reagent (Biomeda, Foster City, CA). Images were obtained using a Leica TCS
SP laser scanning spectral confocal microscope. Confocal image stacks were
edited using Leica confocal software, LCS Lite.

Data Presentation
Data are presented as mean ⫹ SEM. All results are representative of at least
two separate experiments.

RESULTS
Characterization of a CHO Stable Cell Line That Releases
a PLAP Reporter When SREBP-2 Is Processed
To measure SREBP-2 processing, we adopted a reporter
assay devised by Sakai et al. (1998), which allows higher
sample throughput and ready quantification. We created a
stable cell line that expresses the carboxy-terminal half of
human SREBP-2 fused to the secreted form of human placental alkaline phosphatase (PLAP-BP2). This cell line, designated 13A/PS, was highly responsive to changes in sterol
status. Thus, more PLAP was secreted in the presence of the
archetypal statin, compactin, whereas less PLAP was secreted in the presence of 25-HC, a commonly used oxysterol
that is a potent inhibitor of SREBP-2 processing (Figure 1A).
A 16-h incubation was required to observe robust effects on
PLAP secretion (Figure 1A). Figure 1B shows that PLAP-BP2
processing decreased in response to nanomolar concentrations of added 25HC (0.001 mg/ml ⫽ 2.5 nM). We next
determined if inhibition of PI3K/Akt affects SREBP-2 processing using a potent and specific cell-permeable inhibitor
of PI3K, LY294002. Figure 1C shows that LY294002 inhibited
PLAP secretion to a similar extent as 25HC during a 16-h
incubation (cf. Figure 1A). By contrast, its inactive analogue,
LY303511, had no effect (Figure 1D). Another commonly
used PI3K inhibitor, wortmannin, also decreased compactininduced PLAP-BP2 processing (unpublished data). To ensure that the effect of PI3K inhibition was not restricted to
compactin, we tested a panel of statins, many of which are in
current clinical use. For each statin, addition of LY294002
reduced PLAP-BP2 processing to basal levels (Figure 1E).
These data indicate that inhibition of PI3K negates the statininduced activation of SREBP-2.
PLAP-BP2 Processing Is Induced by Cholesterol Depletion
and Reduced by PI3K Inhibition
The ability of statins to increase SREBP-2 processing has
been attributed to its inhibition of cholesterol synthesis and
consequent lowering of cellular cholesterol levels (Yang et
al., 1995; Cheng et al., 1999). However, statins also inhibit
isoprenoid formation, which may impact on PI3K/Akt signaling (Laufs and Liao, 2003). To further investigate how
statins stimulate SREBP-2 processing, we tested whether the
effect could be inhibited by addition of mevalonate, the
product of HMG-CoA reductase. Exogenous mevalonate
2737
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Figure 1. Processing of a PLAP-BP2 fusion protein increases with
compactin treatment and decreases with 25-hydroxycholesterol or
LY294002 treatment. (A) 13A/PS cells, a cell line stably expressing
PLAP-BP2, were incubated for 2, 4, 8, or 16 h in medium B in the
absence (dashed lines) or presence (solid lines) of compactin (CPN,
5 M), and/or in the absence (䡬) or presence (⽧) of 25-hydroxycholesterol (25HC, 1 g/ml). (B) 13A/PS cells were incubated for
16 h in medium B with varying concentrations of 25HC (in g/ml)
in the presence of compactin (5 M). (C) 13A/PS cells were incubated for 2, 4, 8, or 16 h in medium B in the absence (dashed lines)
or presence (solid lines) of compactin (CPN, 5 M) and/or in the
absence (䡬) or presence (Œ) of LY294002 (LY, 20 M). (D) 13A/PS
cells were incubated for 16 h in medium B in the absence (blank) or
presence (shade) of compactin (CPN, 5 M) and/or in the absence
(control) or presence of LY294002 (20 M), LY303511 (20 M). (E)
13A/PS cells were incubated for 16 h in medium B in the absence
(Control) or presence of various statins (1 M: lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin)
and/or in the absence or presence of LY294002 (LY, 20 M). For all
experiments, medium was assayed for PLAP secretion by luminometry, and cell protein was determined. Values are means ⫹ SEM
(from n ⫽ 3 replicate cultures).

suppressed PLAP-BP2 processing stimulated by compactin
treatment (Figure 2A). We then tested if inhibition of a later
step in cholesterol synthesis, after isoprenoid synthesis, also
increases SREBP-2 processing. Inhibition of squalene epoxidase by GR144000X had a similar stimulatory effect on PLAP
secretion as compactin (Figure 2B). Cholesterol delivered in
complex with methyl-␤-cyclodextrin overcame the effect of
the two cholesterol synthesis inhibitors (Figure 2B). Addition of the PI3K/Akt inhibitor, LY294002, similarly decreased PLAP secretion stimulated by the squalene epoxidase inhibitor, GR144000X (Figure 2C). We then tested if
depleting cholesterol in a statin-independent way increased
SREBP-2 processing. As observed with compactin treatment,
cholesterol depletion using hydroxypropyl-␤-cyclodextrin
increased PLAP secretion, which was also reversed by
LY294002 treatment (Figure 2D). Taken together, our results
first support previous work suggesting that statins increase
SREBP-2 processing by reducing cellular cholesterol status
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Figure 2. Effects of cellular cholesterol status and LY294002 treatment on processing of a PLAP-BP2 fusion protein. (A) 13A/PS cells
were incubated for 16 h in medium B in the absence or presence of
compactin (CPN, 5 M) and were coincubated in the absence or
presence of mevalonate (Mev, 5 mM). (B) 13A/PS cells were incubated for 16 h in medium B in the absence or presence of compactin
(CPN, 5 M) and/or an inhibitor of squalene epoxidase (SEi,
GR144000X, 5 M). Cells were coincubated in the absence or presence of cholesterol complexed to methyl ␤-cyclodextrin (chol, 20
g/ml). (C) 13A/PS cells were incubated for 16 h in medium B in
the absence or presence of compactin (CPN, 5 M) and/or an
inhibitor of squalene epoxidase (SEi, GR144000X, 5 M). Cells were
coincubated in the absence or presence of LY294002 (LY, 20 M). (D)
13A/PS cells were incubated for 16 h in medium B containing
varying concentrations of hydroxypropyl-␤-cyclodextrin (HP␤CD,
wt/vol) to deplete cellular cholesterol levels in the absence or
presence of LY294002 (LY, 20 M). For all experiments, medium
was assayed for PLAP secretion by luminometry and cell protein
determined. Values are means ⫹ SEM (n ⫽ 3 replicate cultures).

(Yang et al., 1995; Cheng et al., 1999) and second indicate that
the PI3K/Akt pathway is involved in SREBP-2 processing.
Statin-induced SREBP-2 Processing Is Acutely Reduced by
the PI3K Inhibitor, LY294002
To confirm that the effect of LY294002 occurred at the level
of SREBP-2 processing, we blotted whole cell lysates from
13A/PS cells with an mAb directed against the N-teminal
domain of SREBP-2 (Yang et al., 1995). In agreement with
previous studies (Yang et al., 1995; Cheng et al., 1999), compactin treatment increased mature (nuclear) SREBP-2 (Figure 3A). Treatment with the PI3K inhibitor, LY294002, reduced mature SREBP-2, although to a lesser extent when
compared with 25HC treatment. SCAP protein levels were
unaffected by all treatments (Figure 3A). Time-course experiments showed that LY294002 decreased statin-induced
SREBP-2 processing acutely. After an hour of LY294002
treatment, the relative proportion of mature SREBP-2 decreased by ⬃30% (Figure 3B, lane 3). To address if LY294002
affects the stability of mature SREBP-2, we performed an
overnight incubation in SRD-1 cells that overexpress the
truncated mature form of SREBP-2 (Metherall et al., 1989).
The stability of mature SREBP-2 in SRD-1 cells was unaffected by either treatment with LY294002 or 25HC (Figure
3C). We confirmed this in a shorter time-course experiment
in 13A/PS cells, by coincubating with the cysteine protease
inhibitor, ALLN, to block degradation of nuclear SREBP-2
(Wang et al., 1994; Yang et al., 1995; Hegarty et al., 2005).
Statin-induced SREBP-2 processing was reduced to a similar
extent by LY294002-treatment, either in the absence or presence of ALLN (Figure 3D). The nuclear portion of SREBP-2
Molecular Biology of the Cell

Akt, SREBP, and ER-to-Golgi Transport
Figure 3. SREBP-2 processing is inhibited acutely by
LY294002 treatment without affecting stability of nuclear SREBP-2. (A) 13A/PS cells were incubated for 16 h
in medium B in the absence or presence of compactin (5
M) and were coincubated in the absence or presence of
LY294002 (20 M) or 25HC (1 g/ml). After immunoblotting for SREBP-2, the filter was stripped and reprobed for SCAP. (B) 13A/PS cells were incubated in
medium B in the absence (lane 1) or presence (lanes 2– 6)
of compactin (5 M). After 16 h, cells were refed fresh
medium B, continuing compactin treatment in the absence or presence of LY294002 (20 M) for varying
times (0 – 8 h). (C) SRD-1 cells that overexpress the active
(nuclear) form of SREBP-2 were incubated for 16 h in
medium B in the absence or presence of compactin (5
M) and were coincubated in the absence or presence of
LY294002 (20 M) or 25HC (1 g/ml). (D) 13A/PS cells
were incubated in medium B containing compactin (5
M). After 16 h, cells were refed fresh medium B containing compactin and coincubated for 1 or 2 h in the
absence or presence of LY294002 (20 M) and/or the
cysteine protease inhibitor, ALLN (25 g/ml). For D,
values are mean ⫹ half-range for the 1- and 2-h time
points, where the conditions lacking both LY294002 and
ALLN were set at 1. Total cell lysates (containing 50 g
protein) were subjected to 7.5% SDS-PAGE and immunoblot analysis with anti-SCAP IgG-R139 or antiSREBP-2 IgG-7D4 as described in Materials and Methods.
P and N denote the precursor and cleaved nuclear forms of SREBP-2, respectively. Relative intensity of the N band relative to the total (N⫹P
bands) was quantified by densitometry and presented relative to the vehicle-treated control in each panel. All results shown are representative of at least two separate experiments.

is missing in the PLAP-BP2 construct used in earlier experiments, and yet cleavage of PLAP-BP2 induced by statins
was still inhibited by LY294002 (Figures 1 and 2). Taken
together, these results indicate that LY294002-treatment decreases SREBP-2 processing and not nuclear SREBP-2 protein stability.
LY294002 Has Downstream Effects on SREBP-Target Gene
Expression and Function
Having established that inhibition of PI3K/Akt decreases
SREBP-2 processing, we determined if LY294002 treatment
influences expression of SREBP-2 gene targets. 25HC, well
known to down-regulate SREBP target gene expression
(Yang et al., 1994), was included as a positive control.
LY294002 treatment decreased expression of LDL-R, a key
cholesterol uptake mechanism, in the presence or absence of
compactin (Figure 4, A and B). Expression of the rate-limiting cholesterol biosynthetic enzyme, HMG-CoA reductase,
was also reduced with LY294002 treatment (Figure 4, C and
D). Again, the effect of LY294002 was not as marked as that
observed with 25HC treatment. Similar results were obtained in the stable cell line, 13A/PS (Figure 4, A and C), and
the wild-type parental cell line, CHO-7 (Figure 4, B and D).
LDL-R and HMG-CoA reductase are primarily regulated by
SREBP-2 (Horton et al., 2003). LY294002 treatment also reduced expression of an SREBP-1c gene target, FAS (Figure 4,
E and F). In the absence of compactin, LY294002 treatment
reduced FAS gene expression to a greater extent than 25HC.
This may be due to FAS also being regulated by the liver X
receptor and 25HC being a weak agonist for this nuclear
receptor (DeBose-Boyd et al., 2001). To determine if the
LY294002-mediated decrease in transcription of key lipid
biosynthetic genes translates to decreased lipid synthesis,
CHO-7 cells were metabolically labeled with [14C]acetic acid
in the absence of compactin, and the extent of cholesterol
and fatty acid synthesis was determined. LY294002 treatVol. 17, June 2006

ment decreased synthesis of both cholesterol and fatty acids
by ⬃30% (Figure 4G). Therefore, inhibition of LY294002 on
SREBP-2 processing has downstream consequences, downregulating SREBP-2 (and -1c) target gene expression and
decreasing lipid synthesis.
Statin-induced Akt Phosphorylation Is Abolished by
Treatment with LY294002 But Not with 25HC
Statins have been reported to affect Akt activation. Most
studies report that statins increase Akt phosphorylation
(e.g., Kureishi et al., 2000), but there are also reports of no
effect or a reduction in Akt phosphorylation (e.g., Zhuang et
al., 2005). To examine the effect of compactin on Akt activation in our CHO-based cells, immunoblot analyses were
performed on lysates from treated 13A/PS cells using an
antibody that is specific for Akt phosphorylated at serine
residue 473. Increased Akt phosphorylation was detected as
early as 15 min after exposure to compactin and peaked at
⬃30 min (Figure 5A, lane 3). The extent of Akt phosphorylation declined to untreated levels by 4 h (Figure 5A, lane 6
vs. lane 7). Treatment with the PI3K inhibitor, LY294002,
ablated Akt phosphorylation in the presence (Figure 5A,
lane 8) or absence of compactin (unpublished data). Treatment with hydrogen peroxide increases Akt phosphorylation acutely (Thomas et al., 2002) and was included as a
positive control (Figure 5A, lane 9). The precise mechanism
whereby 25HC induces SCAP-Insig-1 binding to suppress
SREBP-2 processing remains obscure. We tested if this oxysterol also affects Akt phosphorylation. Figure 5B shows a
representative immunoblot, and the relative extent of Akt
phosphorylation was quantified from three separate experiments in Figure 5C. Figure 5, B and C, clearly demonstrates
that 25HC had no effect on compactin-mediated Akt phosphorylation, indicating that the mechanism whereby 25HC
suppresses SREBP-2 processing does not involve Akt phosphorylation.
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Figure 4. LY294002 treatment has downstream effects on SREBPtarget genes and lipid synthesis. 13A/PS (A, C, and E) or CHO-7 (B,
D, F, and G) cells were incubated for 16 h in medium B in the
absence or presence of compactin (CPN, 5 M) and were coincubated in the absence or presence of LY294002 (20 M) or 25HC (1
g/ml). mRNA levels for (A and B) LDL-R, (C and D) HMG-CoA
Reductase, or (E and F) FAS were measured using QRT-PCR, normalized to PBGD mRNA levels. Data are presented relative to
vehicle-treated controls and are means ⫹ SEM (n ⫽ 3 replicate
cultures). (G) CHO-7 cells were incubated for 16 h in medium B
containing [14C]acetic acid in the absence or presence of LY294002
(20 M) or 25HC (1 g/ml). As described in Materials and Methods,
lipid extracts (from equivalent cell proteins) were separated by TLC,
and bands corresponding to authentic standards were visualized by
phosphoimager (24 h- and 72-h exposure, for fatty acid and sterol
synthesis, respectively) and presented relative to the vehicle-treated
control in each panel.

LY294002 Does Not Stimulate Cholesterol Delivery to the
ER and/or Increase SCAP-Insig-1 Binding
Acyl-CoA:cholesterol acyl-transferase (ACAT) is an ER-resident enzyme that catalyzes the esterification of cholesterol
in response to an expanded pool of cholesterol (Lange and
Steck, 1997). We investigated if LY294002 increases cholesterol delivery to the ER by measuring the extent of cholesteryl [14C]oleate formation when 13A/PS cells were incubated with [14C]oleic acid. 25HC is well documented to
stimulate cholesterol esterification (e.g., Du et al., 2004). Unlike 25HC, LY294002 did not affect cholesterol esterification
(Figure 6A). Recent work (Adams et al., 2004) suggests that
25HC-induced binding of the SREBP escort protein, SCAP,
to the ER-retention protein, Insig-1, is independent of cholesterol delivery to the ER. If LY294002 were to increase
cholesterol delivery to the ER regulatory pool or work by an
alternative mechanism like 25HC, we would predict that
LY294002 should also increase SCAP-Insig-1 binding. The
extent of SCAP-Insig-1 binding can be determined by immunoprecipitation of Myc-Insig-1 when Myc-tagged Insig-1
2740

Figure 5. Statin-induced Akt phosphorylation is abolished by
treatment with LY294002 but not with 25HC. (A) 13A/PS cells were
incubated for varying times (0 – 4 h) in medium B in the absence or
presence of compactin (5 M) and were coincubated in the absence
or presence of LY294002 (20 M) or hydrogen peroxide (500 M). (B
and C) 13A/PS cells were incubated for 30 min in medium B in the
presence of compactin (5 M) and were coincubated in the absence
or presence of LY294002 (20 M) or 25HC (1 g/ml). Panel C shows
the relative intensity of the P-Akt band relative to the total Akt band
(means ⫹ SEM) from three separate experiments. There is no error
bar in the compactin only control in C, because this condition was
set at 1 for all three separate experiments. Whole cell lysates (containing 80 g protein) were subjected to 10% SDS-PAGE and immunoblot analysis with anti-Phospho-Akt (Ser473; P-Akt) or antiTotal Akt as described in Materials and Methods. Relative intensity of
the P-Akt band relative to the total Akt band was quantified by
densitometry and presented relative to control in each panel.

and SCAP are coexpressed in SRD-13A cells (Feramisco et
al., 2005). When Myc-Insig-1 was expressed alone, no SCAP
was pulled down by Myc-Insig-1 immunoprecipitation since
this cell line lacks SCAP (Figure 6B, lane 2). The greatest
SCAP-Insig-1 binding was observed when cells were treated
with 25HC (Figure 6B, lane 6), followed by the condition lacking compactin (Figure 6B, lane 3). The least SCAP-Insig-1 binding was observed with compactin alone (Figure 6B, lane 4) or in
combination with LY294002 treatment (Figure 6B, lane 5).
Therefore, these studies indicate that LY294002 does not enhance cholesterol delivery to the ER or retention of the SCAP/
SREBP-2 complex by Insig-1 in the ER.
Akt Inactivation Disrupts ER-to-Golgi Transport
of GFP-SCAP
To determine if Akt inactivation influences the movement of
SCAP, we performed direct fluorescence and immunofluorescence microscopy on SCAP-null cells expressing GFPSCAP. These cells (CHO/pGFP-SCAP) have previously
been used to show that SCAP moves from ER-to-Golgi in a
sterol-dependent manner (Nohturfft et al., 2000). In the absence of compactin, GFP-SCAP had a diffuse, reticular pattern (Figure 7A) that is typical of ER localization. After 4 h of
compactin treatment, there was bright juxtanuclear fluorescence (Figure 7B), representing transport of GFP-SCAP to
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Figure 6. LY294002 does not stimulate cholesterol delivery to the
ER and/or increase SCAP-Insig-1 binding. (A) 13A/PS cells were
incubated for 16 h in medium B containing [14C]oleic acid in the
absence or presence of compactin (5 M) and were coincubated in
the absence or presence of LY294002 (20 M) or 25HC (1 g/ml).
Lipid extracts (from equivalent cell proteins) were separated by TLC
and bands corresponding to authentic cholesteryl oleate standard
were visualized by phosphoimager. Shown are two sets prepared
from duplicate cultures. Relative intensities of the bands were quantified by densitometry and averaged for the two sets. (B) Coimmunoprecipitation of Insig-1 and SCAP. SRD-13A cells set up in
100-mm dishes were transfected for 24 h with the following plasmids: pcDNA3 alone (Mock, lane 1), pCMV-Insig-1-Myc (0.9 g,
lanes 2– 6,) and pTK-SCAP (4.5 g, lanes 3– 6). The total amount of
DNA was adjusted to 6 g/dish with pcDNA3 and/or pTK3 mock
vectors. Cells were incubated for 16 h in medium B in the absence or
presence of compactin (5 M) and were coincubated in the absence
or presence of LY294002 (20 M) or 25HC (1 g/ml). Cells were
then harvested for immunoprecipitation with anti-Myc IgG-9E10
and subjected to 10% SDS-block and immunoblot analysis with
anti-SCAP IgG-R139 or anti-Myc IgG-9E10 as described in Materials
and Methods. Immunoblot analysis showed no Myc-Insig-1 and little
SCAP in the immunoprecipitation supernatants (unpublished data),
consistent with the article in which the method was originally
described (Feramisco et al., 2005). Relative intensity was quantified
by densitometry and presented relative to the vehicle-treated control. All results shown are representative of at least two separate
experiments.

the Golgi (Nohturfft et al., 2000). Thus, this discrete Golgi
localization was abolished when cells were coincubated
with brefeldin A (Figure 7C), an agent which causes Golgi
membranes to fuse with the ER (Sciaky et al., 1997). Coincubation with LY294002 produced less intense and less discrete juxtanuclear fluorescence (Figure 7E), which was distinct from the more diffuse ER fluorescence patterns evident
when ER-to-Golgi transport was inhibited either by treatment with 25HC (Figure 7D) or a 16°C temperature block
(Figure 7F). These observations indicate that LY294002 may
interfere with ER-to-Golgi transport of the SREBP/SCAP
complex. We then tested if a dominant-negative form of Akt
(where the two phosphorylation sites were replaced with
alanines: T308A, S473A; Dimmeler et al., 1999) had a similar
effect on compactin-induced GFP-SCAP transport as pharmacological inhibition of PI3K by LY294002. When cells
expressed this dominant-negative Akt (myc-tagged), GFPSCAP transport to the Golgi was also disrupted (Figure 8,
A–C). By contrast, nonexpressing cells in the same field still
showed pronounced Golgi localization of GFP-SCAP. In
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Figure 7. LY294002 disrupts ER-to-Golgi transport of GFP-SCAP
in CHO Cells. Stably transfected CHO/pGFP-SCAP cells were set
up on glass cover slips as described in Materials and Methods. On day
1, cells were cultured in medium B for 4 h in the absence (A) or
presence (B–F) of compactin (5 M) and were coincubated with (C)
brefeldin A (20 M), (D) 25HC (1 g/ml), or (E) LY294002 (20 M).
All incubations were at 37°C except for F, which was at 16°C.
Representative fields are shown for each condition from repeated
(n ⫽ 5) experiments. Parental cells (SRD-13A) lacking GFP-SCAP
showed no fluorescence under these conditions (unpublished data).

addition, when cells expressed wild-type Akt, GFP-SCAP
transport was unaffected (Figure 8, D–F). To further demonstrate that Akt is involved in SREBP processing, we transiently transfected the SCAP-null SRD-13A cells with plasmids encoding SCAP, the PLAP-BP2 reporter together with
either wild-type Akt or dominant-negative Akt plasmids.
Compactin stimulated PLAP secretion when wild-type Akt
was transfected, whereas when dominant-negative Akt was
transfected, the statin effect was completely abolished (Figure 8G). These observations suggest that inactivation of Akt
by either PI3K inhibition (LY294002) or dominant-negative
Akt transfection disrupts ER-to-Golgi transport of GFPSCAP and therefore inhibits SREBP processing.
IGF-1 Induces SREBP Processing and ER-to-Golgi
Transport of GFP-SCAP, Which Is Inhibited by LY294002
and 25HC
Various growth factors signal cell growth and proliferation
via the Akt pathway whereas the statin model used thus far
may be more related to cholesterol homeostasis than cell
growth or proliferation. To determine if growth factors also
induce SREBP processing and transport of GFP-SCAP to the
Golgi, we used IGF-1 because CHO cells express the IGF-1
receptor endogenously (Luo et al., 2005). Treatment of
13A/PS cells with IGF-1 increased PLAP-BP2 processing in
a dose-dependent manner that was blunted by addition of
LY294002 (Figure 9A). Western blotting analysis confirmed
IGF-1’s ability to increase SREBP-2 processing that was inhibited by treatment with LY294002 or 25HC. (Figure 9B).
Moreover, experiments in CHO/pGFP-SCAP cells (Figure
9C) show that IGF-1-treatment induces GFP-SCAP movement to the Golgi that again could be blocked by treatment
with LY294002 or 25HC. Therefore, IGF-1, a proliferative
stimulus working through Akt (Luo et al., 2005), induces
ER-to-Golgi transport of GFP-SCAP and thereby stimulates
SREBP processing.
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Figure 8. Dominant-negative Akt also disrupts ER-to-Golgi transport of GFP-SCAP in CHO cells and inhibits SREBP-2 processing.
(A–F) Stably transfected CHO/pGFP-SCAP cells were set up on
coverslips as described in Materials and Methods. On day 1, cells were
transfected with dominant-negative Akt (DN-Akt; A–C) or wild
type-Akt (WT-Akt; D–F). On day 2, cells were cultured in medium
B for 4 h in the presence of compactin (5 M). Immunofluorescence
staining was performed as described in Materials and Methods. Representative fields are shown for each condition from repeated (n ⫽
5) experiments. Parental cells (SRD-13A) lacking GFP-SCAP showed
no fluorescence under these conditions (unpublished data). (G)
SCAP-null SRD-13A cells were transiently transfected with pCMVPLAP-BP2 (0.25 g), pTK-SCAP (0.05 g), DN-Akt (0.5 g), or
WT-Akt (0.5 g) in medium A for 24 h. Cells were incubated in
medium B for 16 h in the presence or absence of compactin (CPN, 5
M). Medium was assayed for PLAP secretion by luminometry, and
cell protein was determined. Values are means ⫹ SEM and are
representative of three separate experiments.

DISCUSSION
SREBP-2 is a master regulator of cholesterol homeostasis,
whereas the PI3K/Akt pathway is crucial in regulating cell
growth, proliferation, and survival. Our studies provide
mechanistic insights that link the SREBP-2 and PI3K/Akt
pathways. On the basis of our studies using a PLAP-BP2
expressing cell line (Figures 1 and 2) and confirmed by
immunoblot analysis (Figure 3), we found that the selective
PI3K inhibitor, LY294002, inhibits SREBP-2 processing
rather than affecting protein stability of nuclear SREBP-2.
Various compounds, including sterols, inhibit SREBP processing by altering SCAP conformation and/or increasing
SCAP-Insig-1 binding in the ER (Brown et al., 2002; Yang et
al., 2002; Adams et al., 2003). We showed that LY294002 does
not increase cholesterol delivery to the ER (as assessed by
cholesterol esterification) nor enhance SCAP-Insig-1 binding
(Figure 6). Fluorescence microscopy studies in GFP-SCAP–
expressing cells indicated that inhibition of PI3K/Akt disrupts ER-to-Golgi transport (Figures 7 and 8), whereas stimulation of PI3K/Akt pathway by the proliferative stimulus,
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Figure 9. IGF-1 induces SREBP processing and ER-to-Golgi transport of GFP-SCAP, which is inhibited by LY294002 and 25-hydroxycholesterol. (A) 13A/PS cells were cultured in medium E for 24 h
before the incubation for 16 h in medium E containing various
concentrations of IGF-1 in the absence or presence of LY294002 (20
M). Medium was assayed for PLAP secretion by luminometry, and
cell protein was determined. Values are means ⫹ SEM (from n ⫽ 3
replicate cultures, representative of 3 separate experiments). (B)
13A/PS cells were cultured in medium E for 24 h before the incubation for 16 h in medium E in the absence or presence of IGF-1 (50
nM) and were coincubated in the absence or presence of LY294002
(20 M) or 25HC (1 g/ml). Total cell lysates (containing 50 g
protein) were subjected to 7.5% SDS-PAGE and immunoblot analysis with anti-SREBP-2 IgG-7D4 as described in Materials and Methods. P and N denote the precursor and cleaved nuclear forms of
SREBP-2, respectively. Relative intensity of the N band relative to
the total (N⫹P bands) was quantified by densitometry and presented relative to the vehicle-treated control (lane 1). (C) Stably
transfected CHO/pGFP-SCAP cells were set up on glass coverslips
as described in Materials and Methods. On day 1, cells were cultured
in medium E for 24 h. On day 2, cells were switched to fresh
medium E and treated for 16 h in the absence or presence of IGF-1
(50 nM) and were coincubated with LY294002 (20 M) or 25HC (1
g/ml). Representative fields are shown for each condition from
repeated (n ⫽ 3) experiments. Parental cells (SRD-13A) lacking
GFP-SCAP showed no fluorescence under these conditions (unpublished data).

IGF-1, induced ER-to-Golgi transport of GFP-SCAP (Figure
9). Our data are consistent with an Akt-dependent step in
transport of SCAP/SREBP-2 from the ER to the Golgi, contributing to the control of the proteolytic cleavage of
SREBP-2 to the active form.
ER-to-Golgi transport of proteins initially involves cargo
selection and concentration into specific regions of the ER by
Molecular Biology of the Cell

Akt, SREBP, and ER-to-Golgi Transport

the action of the COPII coat complex (Watanabe and Riezman,
2004). In sterol-depleted conditions, COPII proteins bind to
the SCAP/SREBP complex when added to isolated membranes in vitro (Espenshade et al., 2002; Sun et al., 2005).
Protein phosphorylation, known to modulate many membrane traffic processes throughout the cell, has also been
implicated in transport between the ER and Golgi (Palmer et
al., 2005). Hence, there is evidence that certain proteins
involved in COPII-dependent export from the ER can be
phosphorylated, including COPII components themselves
(Vaughan et al., 2002; Dudognon et al., 2004). Furthermore,
certain kinases have been implicated in ER-to-Golgi traffic,
including protein kinase A (Aridor and Balch, 2000; Lee and
Linstedt, 2000), diacylglycerol kinase delta (Nagaya et al.,
2002), and PCTAIRE kinases, a relatively uncharacterized
branch of the cyclin-dependent kinase family (Palmer et al.,
2005). Ours is the first study to provide evidence that PI3K/
Akt is also involved in ER-to-Golgi transport. However, the
precise target(s) of Akt remains elusive. Our immunofluorescence studies (Figure 8) suggest that GFP-SCAP may
colocalize to some extent with Akt. This was more evident
for wild-type Akt (Figure 8F) than for dominant-negative
Akt (Figure 8C). However, Porstmann et al. (2005) were
unable to identify high-stringency Akt phosphorylation sites
in SREBP proteins, SCAP, Insig or site-1 and -2 proteases.
Moreover, we have been unable to demonstrate any direct
interaction of Akt and SCAP using a coimmunoprecipitation
approach (our unpublished data). Further studies are
needed to identify the precise target(s) of Akt in ER-to-Golgi
transport and to determine if an Akt-dependent step regulates ER-to-Golgi transport of other cargoes besides SCAP/
SREBP-2.
Our studies indicate that inhibition of PI3K/Akt has a
general and fundamental effect on cellular lipid homeostasis. We showed that first, LY294002 blunted the increase in
SREBP-2 processing regardless of how cellular cholesterol
status was depleted or in response to a growth factor, IGF-1.
Second, LY294002 treatment down-regulated the SREBP-2 or
-1c gene targets, LDL-R, HMG-CoA reductase, and FAS, and
also decreased cholesterol and fatty acid synthesis. Therefore, changes in the activity of the PI3K/Akt pathway influences SREBP-2 processing and this has downstream effects
on cellular lipid homeostasis.
Our results confirm previous studies that have linked the
Akt and SREBP pathways (Demoulin et al., 2004; Zhou et al.,
2004; Hegarty et al., 2005; Porstmann et al., 2005). For example, pharmacological inhibition of PI3K/Akt decreased mature SREBP-1 in response to growth factors or insulin
(Demoulin et al., 2004; Zhou et al., 2004; Hegarty et al., 2005).
In addition, Zhou et al. (2004) showed that a constitutively
active form of Akt activated the LDL-R and FAS promoters
in concert with VEGF, whereas dominant-negative Akt
blocked VEGF-induced activation of these promoters. Our
studies extend these findings by clearly demonstrating a role
for PI3K/Akt in cellular cholesterol metabolism via effects
on SCAP transport from the ER to the Golgi and hence
SREBP-2 activation.
We have focused on the effects of PI3K inhibition on
SREBP-2 processing because this transcription factor mainly
regulates cholesterol metabolism (Horton et al., 2003) and
previous studies have mostly focused on SREBP-1. Akt is
also likely to influence transport of SREBP-1 from the ER to
the Golgi and consequent activation, because LY294002 also
decreased fatty acid synthesis and FAS gene expression
(Figure 4). FAS, like other genes involved in fatty acid synthesis, is preferentially regulated by SREBP-1c (Horton et al.,
2003).
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Our data are consistent with previous assertions (Yang et
al., 1995; Cheng et al., 1999) that statins increase SREBP-2
processing by depleting cellular cholesterol because inhibition at a later step in the pathway (catalyzed by squalene
epoxidase) had a similar effect as did depletion of cellular
cholesterol by incubating with low levels of hydroxypropyl␤-cyclodextrin (Figure 2). Moreover, addition of cholesterol
reversed the increase in SREBP-2 processing observed when
cells were treated with statin or a squalene epoxidase inhibitor. Furthermore, statins reduced cholesterol levels in the
ER regulatory pool, as evidenced by less cholesterol esterification by the ER resident protein, ACAT, and decreased
SCAP-Insig-1 binding (Figure 6). Therefore, our studies add
support to previous suggestions that statins increase
SREBP-2 processing by reducing the local concentration of
cholesterol in the ER.
The PI3K/Akt pathway is best known for its role in promoting cell growth, proliferation, and survival through increased glucose utilization and prevention of apoptosis
(Whiteman et al., 2002; Song et al., 2005). Our results with the
growth factor, IGF-1, indicate that a proliferative stimulus,
working through the PI3K/Akt pathway, induces ER-toGolgi movement of SCAP, and activates SREBP-2 processing
(Figure 9). Synthesis of new membrane is an absolute requirement for cell growth and proliferation, and hence a
connection between the SREBP and Akt pathways makes
sense from a teleological perspective. Indeed, Goldstein and
Brown (Goldstein et al., 2002) have used mutant CHO cell
lines to demonstrate that an intact SREBP pathway is required for long-term proliferation. Nohturfft and colleagues
recently reported (Castoreno et al., 2005) that phagocytosisinduced membrane biogenesis was initiated by activation of
SREBP-1a and SREBP-2 without lipid deprivation. In light of
our current data, it would be interesting to determine if the
Akt signaling pathway is involved in phagocytosis-induced
membrane biogenesis.
The oxysterol, 25HC, was used as a positive control in our
experiments, because it is a potent suppressor of SREBP
processing. However, its precise mechanism of action remains unknown. Recent work (Adams et al., 2004) suggests
that 25HC induces SCAP-Insig-1 binding without altering
the conformation of SCAP and proposes the existence of a
25HC sensing protein. Our work indicates that 25HC’s potent suppression of SREBP processing is unlikely to involve
the PI3K/Akt signaling pathway because 25HC had no effect on Akt phosphorylation (Figure 5B).
In terms of implications of our results in vivo, it is worth
noting that activation of Akt by PI3K is associated with
several human cancers (Osaki et al., 2004). It is not known if
overall cholesterol metabolism is normal in patients with
mutations in the PI3K/Akt pathway, but overactive fatty
acid and cholesterol synthesis have been described for various types of tumors (reviewed in Freeman and Solomon,
2004; Menendez and Lupu, 2004). Similarly, it is not clear if
cholesterol metabolism is influenced in mice in which the
various Akt isoforms have been deleted. Interestingly however, constitutively active Akt targeted to liver in mice increased LDL-R expression (Ono et al., 2003), which is consistent
with our finding that inhibition of PI3K/Akt down-regulated
LDL-R expression in CHO cells (Figure 4, A and B). As shown
by us (Figure 5A) and others previously (e.g., Kureishi et al.,
2000), statins can increase Akt activation, but this is unlikely to
be a concern in terms of human cancer risk, because the consensus from large well-controlled trials is that statin therapy
does not increase rates of fatal or nonfatal cancers. Indeed,
recent studies indicate that statin use may even reduce the risk
of certain cancers (Poynter et al., 2005). Further work is re2743
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quired to determine precisely what role SREBP activation plays
in cell transformation and tumor development.
In summary, our studies indicate that there is an Aktdependent step in SCAP/SREBP transport to the Golgi,
adding another input into SREBP activation beside the familiar lipid end products. Our results also highlight a fundamental connection between the SREBP and PI3K/Akt
pathways, which may be reconciled teleologically since synthesis of new membrane is an absolute requirement for cell
growth and proliferation.

Goldstein, J. L., Basu, S. K., and Brown, M. S. (1983). Receptor-mediated
endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol.
98, 241–260.
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